Hub : Traits :

HDL Cholesterol

681 significantly associated models · 171 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	26327671	27882335	3	1	9.3e-09	2.8e-07	3.6e-01	97	ZDHHC18
2	1	39182130	40737589	5	1	5.5e-11	4.0e-10	1.0e+00	100	PABPC4
3	1	93377792	93883331	1	1	1.7e-07	4.1e-07	2.8e-01	95	TMED5
4	1	109098737	110517617	3	1	4.9e-08	6.2e-08	4.1e-01	98	SORT1
5	1	229499636	231115887	1	1	7.9e-21	3.7e-21	1.0e+00	100	GALNT2
6	2	20062043	21544066	1	1	5.8e-08	1.2e-30	3.1e-30	1	HS1BP3
7	2	84849386	86275985	3	1	8.9e-08	1.0e-07	1.4e-01	92	RETSAT
8	2	164657815	166170073	1	1	6.9e-10	2.7e-10	1.0e+00	100	GRB14
9	3	49030828	50448632	1	1	2.9e-07	1.4e-06	5.1e-01	98	RNF123
10	3	52322680	52821177	1	1	1.9e-07	5.6e-07	6.9e-02	87	LOC440957
11	4	87165758	88754060	1	1	4.7e-08	1.2e-06	1.1e-01	89	AFF1
12	6	33856903	35549670	3	1	3.7e-10	3.8e-09	8.3e-01	100	C6orf106
13	7	6170312	6690270	1	1	1.6e-07	1.4e-06	9.8e-01	100	RAC1
14	7	72674074	73738067	2	5	1.1e-09	1.2e-09	1.0e+00	100	BCL7B MLXIPL
15	7	129917130	131315092	1	1	1.7e-08	1.2e-15	1.1e-08	49	RP11-138A9.1
16	8	19064892	20858217	2	4	1.7e-99	9.7e-98	1.9e-01	100	LPL LZTS1
17	9	14472090	15994724	1	1	7.8e-15	1.3e-13	3.9e-01	99	TTC39B
18	9	106846396	108380721	1	1	8.1e-18	1.7e-33	1.8e-17	50	ABCA1
19	11	46010847	48783497	24	2	1.0e-20	1.5e-16	2.2e-01	98	ACP2 NUP160
20	11	60549966	62346131	7	2	7.1e-23	2.2e-22	1.0e+00	100	C11orf10 FEN1
21	11	115953897	117767498	6	6	5.3e-43	1.2e-28	1.0e+00	100	AP006216.12 APOA1 BUD13 ZNF259
22	12	19826892	21533355	1	1	3.4e-08	3.8e-08	1.0e+00	100	PDE3A
23	12	108763672	110729807	7	1	1.8e-15	6.9e-15	2.2e-01	98	KCTD10
24	12	123040985	125270773	9	2	7.7e-16	2.6e-14	3.1e-12	16	CDK2AP1 RP11-380L11.3
25	15	58004888	59737506	2	3	6.1e-42	2.9e-96	1.9e-45	54	ADAM10 LIPC
26	15	62636766	64056437	4	1	1.8e-08	1.9e-08	1.0e+00	100	RP11-244F12.2
27	16	55789570	58178596	10	9	0.0e+00	2.1e-306	NaN	NaN	CETP MT1L NLRC5 OGFOD1 SLC12A3
28	16	66542957	69084178	33	8	7.2e-35	8.4e-33	1.0e+00	100	B3GNT9 DUS2 FHOD1 GFOD2 LCAT NRN1L PRMT7
29	17	36710513	39048774	15	1	1.5e-15	8.7e-14	1.3e-01	96	PGAP3
30	19	8182620	8848856	3	2	4.0e-08	4.0e-08	1.0e+00	100	ANGPTL4 MYO1F
31	19	45162038	45695738	3	1	2.3e-10	4.4e-21	1.9e-18	14	APOC1
32	19	52049899	52574723	1	1	1.5e-07	1.7e-07	1.0e+00	100	FPR3
33	19	54106547	55427510	2	1	1.4e-17	1.4e-15	4.2e-01	99	LILRA3
34	20	43766067	45235570	7	4	8.3e-16	1.9e-22	2.2e-05	81	CTSA MMP9 PLTP ZSWIM1
35	22	21075537	22685340	4	1	3.8e-10	1.1e-08	9.8e-01	100	CCDC116

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.28	2	0	0.0	0.00	1.0e+00	C11orf10 FEN1
Bipolar Disorder or Schizophrenia	1.40	3	0	0.0	0.00	1.0e+00	LCAT PGAP3 PRMT7
Depressed Affect (Nagel 2018)	1.33	2	1	2.2	0.00	1.0e+00	KCTD10 NUP160
Depression (Nagel 2018)	1.39	1	0	0.0	0.00	1.0e+00	NUP160
Intelligence (Savage-Jansen 2018)	1.73	5	2	4.4	-0.45	3.7e-01	FEN1 LCAT NRN1L NUP160 RNF123
Neuroticism (Nagel 2018)	1.28	2	2	4.4	0.00	1.0e+00	KCTD10 NUP160
Schizophrenia (2018)	1.28	2	0	0.0	0.00	1.0e+00	LCAT PRMT7
Schizophrenia vs Biploar Disorder	1.84	1	0	0.0	0.00	1.0e+00	RNF123
Worry (Nagel 2018)	1.35	3	1	2.2	0.00	1.0e+00	KCTD10 LOC440957 NUP160
Alzheimer’s Disease (including proxy)	1.36	1	0	0.0	0.00	1.0e+00	LILRA3
Crohns Disease (2017)	1.98	3	2	4.4	0.00	1.0e+00	CCDC116 FEN1 PGAP3
Irritable Bowel Disease (IBD)	1.69	2	2	4.4	0.00	1.0e+00	CCDC116 PGAP3
Ulcerative Colitis (UC)	1.23	1	1	2.2	0.00	1.0e+00	PGAP3
Reaction Time	1.07	1	0	0.0	0.00	1.0e+00	MMP9
Verbal and Numeric Reasoning (VNR)	1.66	5	0	0.0	0.28	6.4e-01	C11orf10 FEN1 LOC440957 NUP160 RNF123
Age at First Birth	1.43	1	0	0.0	0.00	1.0e+00	RNF123
Coronary Artery Disease (CAD)	2.75	3	1	2.2	0.00	1.0e+00	BUD13 LPL RP11-380L11.3
Crohns Disease (2012)	1.98	3	0	0.0	0.00	1.0e+00	CCDC116 FEN1 PGAP3
Fasting Glucose	2.14	1	1	2.2	0.00	1.0e+00	FEN1
LDL Cholesterol	12.49	12	9	20.0	-0.58	3.1e-02	ABCA1 APOC1 BUD13 C11orf10 C6orf106 CETP FEN1 HS1BP3 NLRC5 SORT1 ZDHHC18 ZNF259
Lupus	1.77	1	1	2.2	0.00	1.0e+00	CCDC116
Primary Biliary Cirrhosis	1.63	1	0	0.0	0.00	1.0e+00	PGAP3
Schizophrenia (2014)	1.33	2	0	0.0	0.00	1.0e+00	LCAT PRMT7
Triglycerides	43.21	23	17	37.8	-0.74	3.2e-06	ACP2 AFF1 BCL7B BUD13 C11orf10 CETP CTSA FEN1 GALNT2 GRB14 HS1BP3 LIPC LOC440957 LPL LZTS1 MLXIPL MMP9 NLRC5 PABPC4 PLTP RP11-380L11.3 ZNF259 ZSWIM1
Type 2 Diabetes (T2D) (2012)	1.82	1	0	0.0	0.00	1.0e+00	RP11-138A9.1
Ulcerative Colitis	1.20	1	1	2.2	0.00	1.0e+00	PGAP3
Blood Eosinophil Count	2.05	20	13	28.9	0.46	2.3e-02	B3GNT9 BUD13 C11orf10 CCDC116 CDK2AP1 DUS2 FEN1 FPR3 LCAT LPL MLXIPL MYO1F NLRC5 PGAP3 RNF123 RP11-138A9.1 TMED5 TTC39B ZDHHC18 ZNF259
Blood Platelet Count	2.82	19	15	33.3	0.04	8.6e-01	ACP2 APOA1 APOC1 BCL7B BUD13 C11orf10 C6orf106 DUS2 FEN1 GALNT2 MLXIPL PABPC4 PGAP3 PLTP RETSAT RP11-244F12.2 TMED5 ZDHHC18 ZNF259
Blood Red Count	2.54	23	17	37.8	0.16	4.6e-01	AFF1 APOA1 C11orf10 C6orf106 CTSA FEN1 FHOD1 GFOD2 GRB14 HS1BP3 LCAT LILRA3 LOC440957 MMP9 NRN1L PABPC4 PGAP3 PRMT7 RP11-138A9.1 RP11-244F12.2 RP11-380L11.3 TMED5 ZSWIM1
Blood White Count	3.22	18	11	24.4	-0.45	4.1e-02	AFF1 APOC1 BCL7B C11orf10 C6orf106 CCDC116 CDK2AP1 CTSA FEN1 LOC440957 MLXIPL NLRC5 NUP160 PGAP3 RETSAT RNF123 RP11-138A9.1 RP11-380L11.3
Heel T-Score	1.46	16	8	17.8	-0.27	3.2e-01	ACP2 AFF1 B3GNT9 C11orf10 CCDC116 CTSA DUS2 FEN1 FPR3 MMP9 PABPC4 RNF123 RP11-244F12.2 RP11-380L11.3 SORT1 ZSWIM1
BMI	1.85	13	9	20.0	-0.20	4.8e-01	ACP2 C6orf106 GALNT2 GRB14 KCTD10 LOC440957 MLXIPL NUP160 OGFOD1 PABPC4 RAC1 RNF123 RP11-380L11.3
Height	1.67	21	15	33.3	0.26	2.1e-01	ACP2 APOC1 BCL7B C11orf10 C6orf106 CCDC116 CTSA DUS2 FEN1 GALNT2 LPL MLXIPL MYO1F NUP160 PABPC4 SLC12A3 SORT1 TMED5 ZDHHC18 ZNF259 ZSWIM1
Waist Hip Ratio (WHR)	5.91	14	9	20.0	-0.30	2.3e-01	ABCA1 BCL7B BUD13 C6orf106 CDK2AP1 DUS2 GRB14 LOC440957 LPL MLXIPL MYO1F PDE3A RP11-138A9.1 RP11-380L11.3
Systolic Blood Pressure	1.16	9	3	6.7	-0.72	2.9e-02	ACP2 CCDC116 FHOD1 GRB14 RAC1 RP11-138A9.1 RP11-244F12.2 RP11-380L11.3 ZDHHC18
Smoking Status	1.13	3	1	2.2	0.00	1.0e+00	C6orf106 NUP160 PGAP3
Allergy or Eczema	1.35	4	2	4.4	-0.55	4.5e-01	C6orf106 CCDC116 PGAP3 TMED5
Cardiovascular Disease	3.24	13	6	13.3	-0.79	1.1e-04	ACP2 BCL7B BUD13 CTSA LPL MLXIPL MYO1F PABPC4 RP11-138A9.1 RP11-244F12.2 SORT1 ZDHHC18 ZNF259
Hypothyroidism (self reported)	1.94	5	3	6.7	0.61	2.8e-01	AFF1 AP006216.12 C11orf10 FEN1 LCAT
Respiratory disease	2.61	5	2	4.4	-0.24	6.9e-01	C11orf10 FEN1 PABPC4 PGAP3 RNF123
Type 2 Diabetes (T2D) (2018)	2.03	5	2	4.4	-0.69	2.0e-01	GRB14 LPL PABPC4 RP11-138A9.1 RP11-380L11.3
Lung FEV1/FVC ratio	1.92	11	7	15.6	0.33	3.0e-01	B3GNT9 C6orf106 CTSA GFOD2 LCAT MYO1F NRN1L PABPC4 PDE3A PRMT7 SORT1
Lung FVC	1.07	6	2	4.4	-0.21	6.8e-01	AFF1 APOA1 C6orf106 LCAT NRN1L PGAP3
Neuroticism	1.35	2	2	4.4	0.00	1.0e+00	KCTD10 NUP160
Hair Pigment	0.20	9	4	8.9	-0.12	7.5e-01	ACP2 C11orf10 FEN1 HS1BP3 MLXIPL NRN1L PABPC4 RP11-138A9.1 ZDHHC18
Tanning	0.29	1	0	0.0	0.00	1.0e+00	MLXIPL
Number of treatments/medications taken	2.48	4	1	2.2	-0.26	7.4e-01	C11orf10 FEN1 RNF123 SORT1
Sensitivity / hurt feelings	1.09	1	1	2.2	0.00	1.0e+00	KCTD10
Frequency of depressed mood in last 2 weeks	1.17	1	0	0.0	0.00	1.0e+00	NUP160
Hearing difficulty/problems: Yes	1.75	1	0	0.0	0.00	1.0e+00	KCTD10
Relative age of first facial hair	1.11	2	0	0.0	0.00	1.0e+00	C6orf106 ZDHHC18
Systolic blood pressure, automated reading	0.71	1	0	0.0	0.00	1.0e+00	RP11-244F12.2
Angina	2.06	2	1	2.2	0.00	1.0e+00	LPL SORT1
Medication: Metformin	1.44	2	0	0.0	0.00	1.0e+00	LPL RP11-138A9.1
Impedance of leg (right)	1.50	8	5	11.1	0.39	2.3e-01	C6orf106 CCDC116 DUS2 LOC440957 MLXIPL OGFOD1 PABPC4 RNF123
Leg fat-free mass (left)	2.17	9	5	11.1	-0.16	6.2e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123
Trunk fat percentage	2.38	9	6	13.3	-0.10	8.0e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Hand grip strength (right)	1.26	2	0	0.0	0.00	1.0e+00	C6orf106 MYO1F
Current tobacco smoking	1.24	1	0	0.0	0.00	1.0e+00	NUP160
Taking other prescription medications	1.56	1	0	0.0	0.00	1.0e+00	RNF123
Age when periods started (menarche)	1.23	2	1	2.2	0.00	1.0e+00	LOC440957 NUP160
Heel bone mineral density (BMD) T-score, automated (left)	1.43	3	1	2.2	0.00	1.0e+00	ACP2 FEN1 RP11-380L11.3
High blood pressure	1.32	3	1	2.2	0.00	1.0e+00	ACP2 RP11-138A9.1 ZDHHC18
Hayfever, allergic rhinitis or eczema	1.27	4	1	2.2	-0.61	3.9e-01	C6orf106 CCDC116 PGAP3 TMED5
Medication: Levothyroxine sodium	1.53	2	1	2.2	0.00	1.0e+00	C11orf10 FEN1
Sitting height	1.78	12	5	11.1	0.26	3.5e-01	ACP2 B3GNT9 BCL7B C11orf10 C6orf106 CCDC116 FEN1 MLXIPL MYO1F NUP160 PABPC4 SLC12A3
Body mass index (BMI)	1.69	9	4	8.9	-0.49	1.8e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 OGFOD1 PABPC4 RNF123 RP11-380L11.3
Impedance of leg (left)	1.51	10	5	11.1	0.25	4.1e-01	C6orf106 CCDC116 DUS2 KCTD10 LCAT LOC440957 MLXIPL OGFOD1 PABPC4 RNF123
Leg predicted mass (left)	2.16	9	5	11.1	-0.16	6.3e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123
Trunk fat mass	2.28	7	5	11.1	-0.02	9.7e-01	C6orf106 DUS2 GRB14 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Waist circumference	1.45	4	3	6.7	-0.99	9.9e-03	C6orf106 MYO1F PABPC4 RNF123
Past tobacco smoking	0.88	2	0	0.0	0.00	1.0e+00	MMP9 PGAP3
Frequency of tenseness / restlessness in last 2 weeks	1.34	1	0	0.0	0.00	1.0e+00	KCTD10
Forced vital capacity (FVC)	1.19	5	3	6.7	-0.26	6.7e-01	ACP2 C6orf106 MYO1F NRN1L NUP160
Heel bone mineral density (BMD) T-score, automated (right)	1.43	4	2	4.4	0.18	8.2e-01	ACP2 B3GNT9 FEN1 RP11-380L11.3
Qualifications: None of the above	1.05	2	1	2.2	0.00	1.0e+00	RNF123 TMED5
Mouth/teeth dental problems	1.14	1	0	0.0	0.00	1.0e+00	KCTD10
Heart attack	2.25	2	1	2.2	0.00	1.0e+00	LPL SORT1
Allergy	1.59	4	1	2.2	0.29	7.1e-01	C6orf106 CCDC116 FEN1 PGAP3
Diabetes (self-reported)	1.44	3	0	0.0	0.00	1.0e+00	PABPC4 RNF123 RP11-380L11.3
Medication: Simvastatin	5.94	9	3	6.7	-0.76	3.9e-03	BUD13 C11orf10 CETP FEN1 LPL NLRC5 SORT1 ZDHHC18 ZNF259
Fluid intelligence score	1.81	2	1	2.2	0.00	1.0e+00	NUP160 RNF123
Neuroticism score	1.33	2	2	4.4	0.00	1.0e+00	KCTD10 NUP160
Weight	2.26	8	6	13.3	-0.12	7.4e-01	C6orf106 GRB14 KCTD10 MLXIPL MYO1F PABPC4 RNF123 RP11-380L11.3
Impedance of arm (right)	2.36	8	5	11.1	0.01	9.9e-01	BCL7B C6orf106 GRB14 LOC440957 MLXIPL RAC1 RNF123 RP11-380L11.3
Arm fat percentage (right)	2.06	9	6	13.3	-0.18	6.5e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Trunk fat-free mass	2.48	12	5	11.1	0.12	6.8e-01	ACP2 BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 OGFOD1 PABPC4 RAC1 RNF123 SORT1
Hip circumference	3.01	10	7	15.6	0.18	5.5e-01	ABCA1 ACP2 BCL7B C6orf106 GRB14 MLXIPL PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Alcohol intake versus 10 years previously	1.64	1	0	0.0	0.00	1.0e+00	PABPC4
Father's age at death	1.70	2	0	0.0	0.00	1.0e+00	LPL SORT1
Worrier / anxious feelings	0.95	1	0	0.0	0.00	1.0e+00	KCTD10
Frequency of tiredness / lethargy in last 2 weeks	1.65	2	1	2.2	0.00	1.0e+00	KCTD10 PABPC4
Falls in the last year	1.17	1	0	0.0	0.00	1.0e+00	KCTD10
Number of live births	1.33	1	0	0.0	0.00	1.0e+00	FEN1
Forced expiratory volume in 1-second (FEV1)	0.96	3	1	2.2	0.00	1.0e+00	ACP2 C6orf106 MYO1F
Pulse rate	1.92	2	1	2.2	0.00	1.0e+00	C11orf10 FEN1
Qualifications: A levels/AS levels or equivalent	1.45	3	1	2.2	0.00	1.0e+00	CTSA RNF123 TMED5
Mouth/teeth dental problems: Dentures	1.33	3	0	0.0	0.00	1.0e+00	PGAP3 RNF123 TMED5
Asthma	2.13	2	2	4.4	0.00	1.0e+00	FEN1 PGAP3
Medication: Cholesterol lowering	7.04	5	4	8.9	-0.75	2.1e-02	BUD13 CETP LPL SORT1 ZNF259
Forced expiratory volume in 1-second (FEV1), Best measure	1.06	3	2	4.4	0.00	1.0e+00	ACP2 C6orf106 MYO1F
Impedance of arm (left)	2.29	6	6	13.3	0.36	3.5e-01	GRB14 LOC440957 MLXIPL RAC1 RNF123 RP11-380L11.3
Arm fat mass (right)	2.01	7	5	11.1	-0.31	4.9e-01	C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-380L11.3
Trunk predicted mass	2.49	13	5	11.1	0.05	8.4e-01	ACP2 BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 OGFOD1 PABPC4 RAC1 RNF123 RP11-380L11.3 SORT1
Standing height	1.72	12	9	20.0	0.31	3.0e-01	ACP2 BCL7B C11orf10 C6orf106 CCDC116 DUS2 FEN1 MLXIPL MYO1F NUP160 SORT1 ZDHHC18
Hair/balding pattern: Pattern 4	1.05	3	1	2.2	0.00	1.0e+00	C11orf10 DUS2 FEN1
Birth weight of first child	1.49	2	0	0.0	0.00	1.0e+00	FHOD1 RAC1
Pulse wave reflection index	1.07	1	0	0.0	0.00	1.0e+00	CTSA
Ever highly irritable/argumentative for 2 days	1.56	1	0	0.0	0.00	1.0e+00	RNF123
Qualifications: O levels/GCSEs or equivalent	1.02	1	0	0.0	0.00	1.0e+00	ZDHHC18
Mouth/teeth dental problems: Bleeding gums	1.57	1	0	0.0	0.00	1.0e+00	KCTD10
Medication: Paracetamol	1.24	1	0	0.0	0.00	1.0e+00	TMED5
Headache pain in last month	1.25	1	0	0.0	0.00	1.0e+00	AFF1
Medication for cholesterol, blood pressure or diabetes	3.96	6	3	6.7	0.83	9.9e-03	BUD13 CETP LPL MLXIPL SORT1 ZNF259
Gout (self-reported)	3.03	1	1	2.2	-0.79	2.1e-01	MLXIPL
Hypothyroidism/myxoedema (self-reported)	1.66	3	0	0.0	0.00	1.0e+00	C11orf10 FEN1 LCAT
Medication: Ventolin 100micrograms inhaler	1.55	1	1	2.2	0.00	1.0e+00	PGAP3
Birth weight	1.68	3	1	2.2	0.00	1.0e+00	BCL7B FHOD1 MLXIPL
Forced vital capacity (FVC), Best measure	1.32	5	2	4.4	0.26	6.7e-01	ACP2 C6orf106 CTSA MYO1F NUP160
Body fat percentage	2.22	8	6	13.3	-0.01	9.8e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 RNF123 RP11-138A9.1 RP11-380L11.3
Leg fat percentage (right)	1.81	8	4	8.9	-0.10	8.1e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 RNF123 RP11-138A9.1 RP11-380L11.3
Arm fat-free mass (right)	2.57	9	5	11.1	0.11	7.4e-01	BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 RAC1 RNF123 SORT1
Comparative body size at age 10	1.06	2	2	4.4	0.00	1.0e+00	B3GNT9 NUP160
Worry too long after embarrassment	1.01	1	0	0.0	0.00	1.0e+00	KCTD10
Seen a psychiatrist for nerves, anxiety, tension or depression	1.15	1	0	0.0	0.00	1.0e+00	FEN1
Wheeze or whistling in the chest in last year	1.78	3	1	2.2	0.00	1.0e+00	FEN1 PGAP3 RNF123
Age at first live birth	1.25	1	1	2.2	0.00	1.0e+00	RNF123
Qualifications: College or University degree	1.49	2	2	4.4	0.00	1.0e+00	RNF123 TMED5
Medication for pain relief, constipation, heartburn	1.51	1	0	0.0	0.00	1.0e+00	C6orf106
Neck or shoulder pain in last month	1.32	1	0	0.0	0.00	1.0e+00	PABPC4
Medication: Blood pressure	1.66	1	0	0.0	0.00	1.0e+00	ACP2
Angina (self-reported)	2.11	2	2	4.4	0.00	1.0e+00	LPL SORT1
Medication: Allopurinol	2.34	2	1	2.2	-1.00	2.2e-04	MLXIPL ZDHHC18
Medication: Omeprazole	1.36	1	0	0.0	0.00	1.0e+00	C6orf106
Mean time to correctly identify matches	1.03	1	0	0.0	0.00	1.0e+00	MMP9
Whole body fat mass	2.17	7	4	8.9	-0.23	6.2e-01	C6orf106 GALNT2 GRB14 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Leg fat mass (right)	2.08	4	4	8.9	0.22	7.8e-01	C6orf106 GRB14 RNF123 RP11-380L11.3
Arm predicted mass (right)	2.59	10	5	11.1	0.01	9.7e-01	BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 PABPC4 RAC1 RNF123 SORT1
Pulse rate, automated reading	2.66	8	6	13.3	-0.76	1.8e-02	C11orf10 C6orf106 FEN1 LOC440957 MLXIPL PABPC4 PDE3A PGAP3
Alcohol intake frequency.	1.60	3	1	2.2	-0.97	1.1e-03	MLXIPL PGAP3 RNF123
Comparative height size at age 10	1.51	8	6	13.3	0.28	5.0e-01	ACP2 C6orf106 CCDC116 DUS2 MYO1F NUP160 SORT1 TMED5
Suffer from 'nerves'	1.50	1	1	2.2	0.00	1.0e+00	NUP160
Overall health rating	1.34	2	0	0.0	0.00	1.0e+00	C6orf106 RNF123
Age at last live birth	1.07	1	1	2.2	0.00	1.0e+00	RNF123
Medication: Aspirin	2.41	2	1	2.2	0.00	1.0e+00	LPL SORT1
Knee pain experienced in last month	1.49	2	0	0.0	0.00	1.0e+00	PABPC4 RNF123
Hypertension (Self-reported)	1.33	2	1	2.2	0.00	1.0e+00	ACP2 RP11-138A9.1
Illnesses of father: Heart disease	2.29	2	1	2.2	0.00	1.0e+00	LPL SORT1
Illnesses of siblings: Diabetes	1.33	1	0	0.0	0.00	1.0e+00	RP11-380L11.3
Smoking status: Previous	0.98	1	0	0.0	0.00	1.0e+00	MMP9
Forced expiratory volume in 1-second (FEV1), predicted	1.37	3	1	2.2	0.00	1.0e+00	ACP2 C6orf106 MYO1F
Whole body fat-free mass	2.35	12	5	11.1	0.04	8.9e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F NUP160 OGFOD1 PABPC4 RAC1 RNF123 SORT1
Leg fat-free mass (right)	2.16	9	5	11.1	-0.14	6.8e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123
Arm fat percentage (left)	2.15	9	6	13.3	-0.18	6.4e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Mood swings	1.38	1	0	0.0	0.00	1.0e+00	NUP160
Loneliness, isolation	1.48	1	1	2.2	0.00	1.0e+00	NUP160
Long-standing illness, disability or infirmity	1.39	1	0	0.0	0.00	1.0e+00	CCDC116
Diabetes diagnosed by doctor	1.51	4	0	0.0	-0.98	1.8e-02	PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Medication for cholesterol	2.64	2	2	4.4	0.00	1.0e+00	RP11-138A9.1 SORT1
Back pain experienced in last month	1.16	1	0	0.0	0.00	1.0e+00	C6orf106
Asthma (self-reported)	2.24	2	2	4.4	0.00	1.0e+00	FEN1 PGAP3
Medication: Aspirin	2.39	2	1	2.2	0.00	1.0e+00	LPL SORT1
Smoking status: Current	1.25	1	0	0.0	0.00	1.0e+00	NUP160
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.07	1	1	2.2	0.00	1.0e+00	PGAP3
Whole body water mass	2.35	12	5	11.1	0.04	8.9e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F NUP160 OGFOD1 PABPC4 RAC1 RNF123 SORT1
Leg predicted mass (right)	2.16	9	5	11.1	-0.14	6.8e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123
Arm fat mass (left)	2.05	7	5	11.1	-0.31	5.0e-01	C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-380L11.3
Average weekly champagne plus white wine intake	2.11	2	1	2.2	0.00	1.0e+00	C11orf10 FEN1
Miserableness	1.38	2	0	0.0	0.00	1.0e+00	KCTD10 NUP160
Medication: Blood pressure	1.98	2	1	2.2	0.00	1.0e+00	ACP2 RP11-138A9.1
Supplements: Fish oil (including cod liver oil)	1.41	1	0	0.0	0.00	1.0e+00	FEN1
High cholesterol (Self-reported)	10.18	11	6	13.3	-0.61	1.2e-02	ABCA1 APOC1 BCL7B BUD13 FEN1 HS1BP3 LPL MLXIPL SORT1 ZDHHC18 ZNF259
Medication: Paracetamol	1.04	1	0	0.0	0.00	1.0e+00	TMED5
Medication: Atorvastatin	5.76	5	3	6.7	-0.01	9.8e-01	ABCA1 BUD13 LPL SORT1 ZNF259
Ever smoked	1.07	1	0	0.0	0.00	1.0e+00	PGAP3
Basal metabolic rate	2.30	10	5	11.1	-0.13	6.8e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123 SORT1
Leg fat percentage (left)	1.82	8	5	11.1	-0.15	7.2e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 RNF123 RP11-138A9.1 RP11-380L11.3
Arm fat-free mass (left)	2.39	9	4	8.9	0.06	8.6e-01	BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 RAC1 RNF123 SORT1
Irritability	1.46	3	0	0.0	0.00	1.0e+00	ANGPTL4 FEN1 KCTD10
Diastolic blood pressure, automated reading	1.12	2	0	0.0	0.00	1.0e+00	MLXIPL PDE3A
Myopia	1.49	1	0	0.0	0.00	1.0e+00	FEN1
Vascular/heart problems diagnosed by doctor	1.35	2	1	2.2	0.00	1.0e+00	ACP2 RP11-138A9.1
Cholesterol lowering medication	7.37	8	6	13.3	-0.40	2.5e-01	ABCA1 BUD13 LPL RP11-138A9.1 RP11-380L11.3 SORT1 ZDHHC18 ZNF259
Medication: Omeprazole (e.g. Zanprol)	1.21	1	0	0.0	0.00	1.0e+00	C6orf106
Pain experienced in last month	1.42	2	1	2.2	0.00	1.0e+00	KCTD10 PABPC4
Heart attack/myocardial infarction (self-reported)	2.26	2	1	2.2	0.00	1.0e+00	LPL SORT1
Impedance of whole body	1.89	9	4	8.9	0.45	1.4e-01	C6orf106 DUS2 GRB14 LCAT LOC440957 MLXIPL OGFOD1 RNF123 RP11-380L11.3
Leg fat mass (left)	2.10	5	4	8.9	0.24	7.0e-01	C6orf106 GRB14 NUP160 RNF123 RP11-380L11.3
Arm predicted mass (left)	2.46	10	4	8.9	-0.02	9.5e-01	BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 PABPC4 RAC1 RNF123 SORT1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	15	0.44	1.7
GTEx	Adipose Visceral Omentum	12	0.61	1.7
GTEx	Adrenal Gland	6	0.42	1.8
GTEx	Artery Aorta	9	0.31	1.6
GTEx	Artery Coronary	6	0.52	1.7
GTEx	Artery Tibial	9	0.25	1.6
GTEx	Brain Caudate basal ganglia	2	0.22	1.6
GTEx	Brain Cerebellar Hemisphere	7	0.48	1.7
GTEx	Brain Cerebellum	6	0.31	1.7
GTEx	Brain Cortex	2	0.20	1.8
GTEx	Brain Frontal Cortex BA9	3	0.33	1.7
GTEx	Brain Hippocampus	3	0.59	1.8
GTEx	Brain Hypothalamus	3	0.52	1.9
GTEx	Brain Nucleus accumbens basal ganglia	5	0.59	1.6
GTEx	Brain Putamen basal ganglia	5	0.82	1.9
GTEx	Breast Mammary Tissue	7	0.37	1.6
GTEx	Breast Mammary Tissue (Male)	2	0.17	1.4
GTEx	Breast Mammary Tissue (Female)	7	0.44	1.7
GTEx	Cells EBV-transformed lymphocytes	4	0.29	1.7
GTEx	Cells Transformed fibroblasts	22	0.54	2.0
GTEx	Colon Sigmoid	2	0.14	1.5
GTEx	Colon Transverse	9	0.45	1.7
GTEx	Esophagus Gastroesophageal Junction	4	0.29	1.6
GTEx	Esophagus Mucosa	17	0.53	1.8
GTEx	Esophagus Muscularis	10	0.32	1.6
GTEx	Heart Atrial Appendage	9	0.58	1.8
GTEx	Heart Left Ventricle	11	0.74	2.0
GTEx	Liver	3	0.43	1.7
GTEx	Lung	13	0.47	1.6
GTEx	Muscle Skeletal	9	0.32	1.6
GTEx	Nerve Tibial	25	0.59	1.7
GTEx	Ovary	1	0.11	1.7
GTEx	Pancreas	5	0.31	1.7
GTEx	Pituitary	3	0.27	1.6
GTEx	Prostate	2	0.25	1.9
GTEx	Skin Not Sun Exposed Suprapubic	12	0.50	1.7
GTEx	Skin Sun Exposed Lower leg	17	0.48	1.8
GTEx	Small Intestine Terminal Ileum	3	0.66	1.6
GTEx	Spleen	5	0.36	1.6
GTEx	Stomach	2	0.14	1.6
GTEx	Testis	11	0.36	1.7
GTEx	Thyroid	16	0.41	1.7
GTEx	Uterus	2	0.36	1.5
GTEx	Vagina	2	0.32	1.7
GTEx	Whole Blood	10	0.52	1.6
METSIM	Adipose	27	0.60	1.9
NTR	Blood	21	0.88	2.0
ROSMAP	Brain Pre-frontal Cortex	12	0.28	1.6
YFS	Blood	26	0.57	1.8
CommonMind	Brain Pre-frontal Cortex	23	0.44	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	6	0.39	1.5
The Cancer Genome Atlas	Breast Invasive Carcinoma	18	0.43	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	6	0.58	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	11	0.57	1.9
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.15	1.4
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.41	1.6
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	16	0.62	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	21	0.54	2.0
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	12	0.62	2.5
The Cancer Genome Atlas	Brain Lower Grade Glioma	19	0.47	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	9	0.86	2.0
The Cancer Genome Atlas	Lung Adenocarcinoma	14	0.50	2.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	14	0.59	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	4	0.27	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	9	0.57	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	2	0.16	1.5
The Cancer Genome Atlas	Prostate Adenocarcinoma	22	0.50	2.0
The Cancer Genome Atlas	Rectum Adenocarcinoma	4	0.62	1.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	5	0.50	1.7
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.00	1.4
The Cancer Genome Atlas	Stomach Adenocarcinoma	11	0.69	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.33	1.7
The Cancer Genome Atlas	Thyroid Carcinoma	21	0.43	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.21	1.5